Alex Blyth's Interview about how LIfT came to be, and why we need to move on from mouse models

The Business of Biotech interviews serial inventor and entrepreneur Alex Blyth who had long held interests in health and science, but losing his mom to pancreatic cancer was the inflection point that launched LIfT Biosciences in 2016. Now, the preclinical company is on a mission to develop the world's first 'off-the-shelf' cell therapy to destroy all solid tumors, irrespective of strain or mutation, beginning with pancreatic cancer. On this episode of the Business of Biotech, Blyth shares the company's scientific approach and progress, and we explore the shortcomings of legacy clinical protocols including the inherent problems and limitations of mouse models.


Stay up-to-date with our progress and latest news

Thanks for subscribing!